Tentando aprender a traduzir a partir dos exemplos de tradução humana.
A partir de tradutores profissionais, empresas, páginas da web e repositórios de traduções disponíveis gratuitamente
frequency categories were determined from the crude incidence rate reported for each adverse reaction in the pivotal clinical study (n = 189).
il-kategoriji tal-frekwenzi kienu determinati mir-rata ta’ inċidenza għal kull elf persuna rrappurtata għal kull reazzjoni avversa fl-istudju kliniku ewlieni (n = 189).
frequency categories were determined from the crude incidence rate reported for each adverse reaction in a dataset of pooled clinical studies (n = 2,044).
il-kategoriji tal-frekwenzi huma ddeterminati mir-rata ta’ inċidenza kull elf persuna rrapportata għal kull reazzjoni avversa f’sett tad-dejta ta’ studji kliniċi miġburin flimkien (n = 2,044).
description and management of neutropenia and thrombocytopenia including incidence rates from clinical trials
deskrizzjoni u mmaniġġjar ta’ newtropenija u tromboċitopenija li tinkludi rati ta’ inċidenzi minn studji kliniċi u esperjenza ta’ wara t-tqegħid fis-suq
in clinical trials, the crude incidence rate of malignancy was the same in the kineret-treated patients and the placebo-treated patients and did not differ from that in the general population.
fi studji kliniċi, ir- rata ta 'l- inċidenza ta ’ tumuri malinni kienet l- istess għall- pazjenti kkurati b’ kineret u għall- pazjenti li ngħataw il- plaċebo u ma kienitx differenti minn dik fil- popolazzjoni ġenerali.
description of the risk of progression to aml in mds patients including incidence rates from clinical trials
deskrizzjoni tar-riskju ta’ progressjoni għal aml f’pazjenti b’mds li jinkludu rati ta’ inċidenza minn provi kliniċi
a low incidence rate of arterial thromboembolic events was observed in the eylea clinical trials in patients with amd, dme, rvo and myopic cnv.
kienet osservata rata baxxa ta’ inċidenza ta’ avvenimenti tromboemboliċi arterjali fil-provi kliniċi b’eylea f’pazjenti b’amd, dme, rvo u cnv mijopika.
description and management of thromboembolic risk including incidence rates from clinical trials and post-marketing experience
deskrizzjoni u mmaniġġjar ta’ riskju tromboembolitiku li tinkludi rati ta’ inċidenzi minn studji kliniċi
a reduction of 27.9 % in the incidence rate of accidents leading to absences of more than three days was achieved in the eu between 2007 and 201113.
bejn l-2007 u l-2011 inkiseb tnaqqis ta' 27.9% fir-rata ta' inċidenza ta' aċċidenti li jwasslu għal assenza ta' aktar minn tlett ijiem13.
from post marketing surveillance with interpandemic trivalent vaccines, the following adverse events have been reported very rarely, even if an exact incidence rate cannot be precisely calculated:
minn sorveljanza b’tilqim trivalenti interpandemiku wara li l-prodott tpoġġa fis-suq, il-każijiet avversi li ġejjin kienu rrappurtati b’mod rari ħafna, anki jekk rata eżatta ta’ inċidenza ma tistax tiġi kkalkulata b’mod preċiż:
in clinical trials, the incidence rates of hypoglycemia were comparably low in patients taking linagliptin in combination with metformin or metformin alone.
fil-provi kliniċi, ir-rati ta’ inċidenza ta’ ipogliċemija kienu komparattivament baxxi f’pazjenti li kienu qed jieħdu linagliptin flimkien ma’ metformin jew metformin waħdu.
comparison of incidence rates across different assays is not appropriate, as the ecl assay was developed to be more sensitive and drug tolerant than the previous elisa assay.
mhux xieraq tqabbil tar-rati ta’ inċidenza fl-analiżijiet differenti, billi l-analiżi ecl ġiet żviluppata sabiex tkun iżjed sensittiva u tolleranti għall-mediċina mill-analiżi elisa preċedenti.
examine the reasons for the different incidence rates of occupational accidents in the member states and discuss their experience of innovative solutions which have proved effective;
jeżamina r-raġunijet li qed iwasslu għal differenzi fir-rati ta’ diżgrazzji fuq il-post tax-xogħol fl-istati membri u jaqsmu l-esperjenzi tagħhom li jikkonċernaw soluzzjonijiet innovattivi li taw prova ta’ l-effiċjenza tagħhom.